CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
placebo +1 moredrug
Likely dose
placebo 0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00729300
NCT00729300Phase 2Completed

Laboratory Models of Cocaine Self-administration

Baylor College of Medicine·interventional·Posted Aug 7, 2008·Updated Jul 19, 2023

In Brief

A Phase 2 clinical trial evaluating placebo and disulfiram for Cocaine Addiction. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The problem of cocaine dependence remains a major medical, social, and legal concern. Several studies have suggested that disulfiram may be beneficial for the treatment of cocaine dependence. A common assumption has been that disulfiram treatment, by increasing DA availability, enhances the aversive aspects of stimulants. This study aims to measure plasma activity in those with the C/C DBH genotype, which is associated with higher DBH activity subsequently making the disulfiram treatment more effective, as well as determine the effects of treatment with disulfiram on cocaine self-administration using a human laboratory model of cocaine self-administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2008
Enrollment StartApr 1, 2006
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10.2 yearsPosted 17.9 years ago

Interventions

placebodrug

0mg daily

disulfiramdrug

250mg daily